|Videos|March 9, 2023

CAR-T in R/R MM: Key Safety and Efficacy Data from the KarMMA and CARTITUDE-1 Trials

Author(s)Sagar Lonial, MD, FACP, Krina K. Patel, MD, MSc, Hana Safah, MD

Dr Sagar Lonial highlights efficacy and safety data from the KarMMA and CARTITUDE-1 clinical trials.

Episodes in this series

$EP. 1 Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma (R/R MM)$

EP. 1 Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma (R/R MM)

EP. 2 Case 1: Treatment of R/R MM with a BCMA-Directed Bispecific Antibody

EP. 2 Case 1: Treatment of R/R MM with a BCMA-Directed Bispecific Antibody

EP. 3 MajesTEC-1: Teclistamab in R/R MM Treatment

EP. 3 MajesTEC-1: Teclistamab in R/R MM Treatment

EP. 4 Selecting Patients with R/R MM for Treatment With Bispecifics

EP. 4 Selecting Patients with R/R MM for Treatment With Bispecifics

EP. 5 Infection Prevention and Management in Patients Receiving BMCA-Directed Bispecific

EP. 5 Infection Prevention and Management in Patients Receiving BMCA-Directed Bispecific

EP. 6 Selecting an Appropriate BCMA-Directed Bispecific for Patients with R/R MM

EP. 6 Selecting an Appropriate BCMA-Directed Bispecific for Patients with R/R MM

EP. 7 DREAMM-2: Belantamab Mafodotin for the Treatment of R/R MM

EP. 7 DREAMM-2: Belantamab Mafodotin for the Treatment of R/R MM

EP. 8 Case 2: Treatment of R/R MM with BCMA-Directed CAR T-Cell Therapy

EP. 8 Case 2: Treatment of R/R MM with BCMA-Directed CAR T-Cell Therapy

EP. 9 CAR-T in R/R MM: Key Safety and Efficacy Data from the KarMMA and CARTITUDE-1 Trials

EP. 9 CAR-T in R/R MM: Key Safety and Efficacy Data from the KarMMA and CARTITUDE-1 Trials

EP. 10 Selecting the Appropriate CAR T-Cell Therapy in R/R MM

EP. 10 Selecting the Appropriate CAR T-Cell Therapy in R/R MM

EP. 11 Case 3: Sequencing BCMA-Directed Therapies for R/R MM

EP. 11 Case 3: Sequencing BCMA-Directed Therapies for R/R MM

EP. 12 Unmet Needs in R/R MM and Clinical Practice Pearls

EP. 12 Unmet Needs in R/R MM and Clinical Practice Pearls

Related Content

FDA Grants RMAT Designation to Allogeneic CAR T for R/R Multiple Myeloma

ByJonah Feldman

April 1st 2026

Pivotal Trial Initiated for Inobrodib Combination in R/R Multiple Myeloma

ByJonah Feldman

March 31st 2026

Phase 1b Trial Initiated for Cemsidomide/Elranatamab in R/R Myeloma

ByJonah Feldman

March 27th 2026

Novel Combinations Showcase Post CAR T Myeloma Role For Mezigdomide

ByPaul G. Richardson, MD

March 27th 2026

Distinguishing Strategic Roles of CELMoDs in Multiple Myeloma

ByPaul G. Richardson, MD

March 24th 2026

Latest CME

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Rocky Mountain Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Rocky Mountain Oncology Society

Seth A. Wander, MD, PhD; Kara M. Schenk, MD

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | North Carolina Oncology Association

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | North Carolina Oncology Association

Marla D. Lipsyc-Sharf, MD; Yan Ji, MD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Kimberly Ku, MD

43rd Annual Miami Breast Cancer Conference®

43rd Annual Miami Breast Cancer Conference®

Patrick I. Borgen, MD; Reshma Jagsi, MD, DPhil; Hope S. Rugo, MD, FASCO

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics, and Beyond

In-Person Event

Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics, and Beyond

May 22, 2026

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Establishing the Rationale for ADC and ICI Combinations in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Breaking Down the Rationale for Targeting TROP2 in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

24th Annual International Congress on the Future of Breast Cancer® East

24th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD